Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.56 |
| ▸ | MAPK7 | Q13164 | 4/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | INSR | P06213 | 4/20 | 0.53 |
| ▸ | ROS1 | P08922 | 3/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.53 |
| ▸ | PLK4 | O00444 | 2/20 | 0.53 |
| ▸ | GAK | O14976 | 2/20 | 0.53 |
| ▸ | ERN1 | O75460 | 2/20 | 0.53 |
| ▸ | STK10 | O94804 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | FES | P07332 | 2/20 | 0.53 |
| ▸ | YES1 | P07947 | 2/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | HCK | P08631 | 2/20 | 0.53 |
| ▸ | FER | P16591 | 2/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150135 | 0.94 | ALK (0.64) | ALKMAPK7BRD4INSRROS1 | |
| SCHEMBL19921077 | 0.89 | MAPK7 (0.54) | ALKMAPK7BRD4INSRROS1 | |
| SCHEMBL21099619 | 0.88 | LRRK2 (0.53) | ALKMAPK7BRD4INSRIGF1R | |
| SCHEMBL21150649 | 0.86 | ALK (0.52) | ALKMAPK7INSRROS1BMPR1B | |
| SCHEMBL19867338 | 0.83 | ALK (0.71) | ALKMAPK7INSRROS1BMPR1B | |
| SCHEMBL19921103 | 0.82 | ALK (0.78) | ALKMAPK7BRD4INSRROS1 | |
| SCHEMBL12729305 | 0.82 | ALK (0.61) | ALKMAPK7INSRROS1BMPR1B | |
| SCHEMBL21099488 | 0.81 | ALK (0.73) | ALKMAPK7INSRROS1BMPR1B | |
| SCHEMBL21150935 | 0.81 | ALK (0.82) | ALKMAPK7INSRROS1BMPR1B | |
| SCHEMBL21099617 | 0.81 | LRRK2 (0.53) | ALKMAPK7BRD4INSREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885MAPK7 1592/4885BRD4 3273/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885MAPK7 1592/4885BRD4 3273/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | ALK 1/4885MAPK7 1592/4885BRD4 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.